These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 22304668)

  • 1. Improving rates of herpes zoster vaccination with a clinical decision support system in a primary care practice.
    Chaudhry R; Schietel SM; North F; Dejesus R; Kesman RL; Stroebel RJ
    J Eval Clin Pract; 2013 Apr; 19(2):263-6. PubMed ID: 22304668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoster vaccine live.
    Kockler DR; McCarthy MW
    Pharmacotherapy; 2007 Jul; 27(7):1013-9. PubMed ID: 17594207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.
    Lu PJ; Euler GL; Harpaz R
    Am J Prev Med; 2011 Feb; 40(2):e1-6. PubMed ID: 21238856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
    Lu PJ; Euler GL; Jumaan AO; Harpaz R
    Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella zoster virus redux.
    Gelb LD
    Herpes; 2009 Jan; 15(3):62-3. PubMed ID: 19306605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modelling the impact of vaccination on the epidemiology of varicella zoster virus].
    Bonmarin I; Santa-Olalla P; Lévy-Bruhl D
    Rev Epidemiol Sante Publique; 2008 Oct; 56(5):323-31. PubMed ID: 18951741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
    Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
    Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination.
    Elkin Z; Cohen EJ; Goldberg JD; Gillespie C; Li X; Jung J; Cohen M; Park L; Perskin MH
    Cornea; 2013 Jul; 32(7):976-81. PubMed ID: 23449488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.
    de Boer PT; Pouwels KB; Cox JM; Hak E; Wilschut JC; Postma MJ
    Vaccine; 2013 Feb; 31(9):1276-83. PubMed ID: 23306360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications].
    Marino MG; Bagnato B; Torella I; Franco E
    Ig Sanita Pubbl; 2009; 65(3):299-311. PubMed ID: 19629155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine.
    Hurley LP; Harpaz R; Daley MF; Crane LA; Beaty BL; Barrow J; Babbel C; Marin M; Steiner JF; Davidson A; Dickinson LM; Kempe A
    J Infect Dis; 2008 Mar; 197 Suppl 2():S216-23. PubMed ID: 18419400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with herpes zoster vaccination status and acceptance of vaccine recommendation in community pharmacies.
    Teeter BS; Garza KB; Stevenson TL; Williamson MA; Zeek ML; Westrick SC
    Vaccine; 2014 Sep; 32(43):5749-54. PubMed ID: 25171848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the advisory committee on immunization practices' recommendations for use of herpes zoster vaccine.
    Weaver BA;
    J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S31-3. PubMed ID: 22086893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(44):1528. PubMed ID: 22071592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination.
    Cheetham TC; Marcy SM; Tseng HF; Sy LS; Liu IL; Bixler F; Baxter R; Donahue JG; Naleway AL; Jacobsen SJ
    Mayo Clin Proc; 2015 Jul; 90(7):865-73. PubMed ID: 26051268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Pharmacist Interventions on Herpes Zoster Vaccination Rates.
    Eid DD; Meagher RC; Lengel AJ
    Consult Pharm; 2015 Aug; 30(8):459-62. PubMed ID: 26260642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why should older adults receive the shingles vaccine?
    Harkness TL
    J Gerontol Nurs; 2010 Oct; 36(10):51-5. PubMed ID: 20506935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing use of the vaccine against zoster through recommendation and administration by ophthalmologists at a city hospital.
    Jung JJ; Elkin ZP; Li X; Goldberg JD; Edell AR; Cohen MN; Chen KC; Perskin MH; Park L; Cohen EJ
    Am J Ophthalmol; 2013 May; 155(5):787-95. PubMed ID: 23394910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
    Betts RF
    J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.